Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H25ClN2O.ClH |
| Molecular Weight | 429.382 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(Cl)C=C3)C4=CC(=NO4)C5=CC=C(C)C=C5
InChI
InChIKey=IZMZEMAKFSYLMD-SXBQIKTFSA-N
InChI=1S/C24H25ClN2O.ClH/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2;/h3-10,14,19-20,22,24H,11-13H2,1-2H3;1H/t19-,20+,22+,24-;/m0./s1
| Molecular Formula | C24H25ClN2O |
| Molecular Weight | 392.921 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
RTI-336 was developed as a selective dopamine transporter (DAT) inhibitor. It is known that DAT inhibitors have been developed as a promising treatment approach for cocaine dependence. RTI-336 can be a useful adjunct in the treatment of cocaine dependence because preclinical data has shown that this drug inhibits DAT with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity. RTI-336 participated in phase I clinical trial where it showed the excellent safety and tolerability, and thus further studies in humans are warranted.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. | 2018 |
|
| Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. | 2006-12-28 |
|
| Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. | 2006-03-24 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00808119
RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:32:29 GMT 2025
by
admin
on
Mon Mar 31 19:32:29 GMT 2025
|
| Record UNII |
667440B6Z7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
667440B6Z7
Created by
admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
|
PRIMARY | |||
|
11524766
Created by
admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
|
PRIMARY | |||
|
C506585
Created by
admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
|
PRIMARY | |||
|
204069-50-1
Created by
admin on Mon Mar 31 19:32:29 GMT 2025 , Edited by admin on Mon Mar 31 19:32:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |